Healthcare & Insurance
Novartis receives European Commission approval for self-administration of Xolair® across all indications
The EC approval underscores the long-term safety and efficacy of Xolair demonstrated in clinical studies and by 13 years of real-world use in Europe[1] Xolair® (omalizumab) prefilled syringe (PFS) is the first and only biologic to receive European Commission (EC) approval for self-administration
Thursday, December 13, 2018
Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
RADNOR, Pa., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or the “Company”) announced the pricing of an underwritten public offering of 12,000,000 shares of common stock at a public offering price of $3.75 per share. The total public offering
Thursday, December 13, 2018
Zynerba Pharmaceuticals Announces Sustained Improvements in Emotional and Behavioral Symptoms of Fragile X Syndrome through 12 Months of Treatment
- Patients Experienced a 77% Improvement in Aberrant Behaviors Associated with Social Avoidance Compared to Baseline after One Year of ZYN002 Treatment - - Presentation Today at the 57th Annual Meeting of the American College of Neuropsychopharmacology - DEVON, Pa., Dec. 12, 2018 (GLOBE
Wednesday, December 12, 2018
Synthorx Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN DIEGO, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Synthorx, Inc. (Nasdaq: THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced the closing of its
Wednesday, December 12, 2018
Idera Pharmaceuticals to Provide ILLUMINATE-204 Clinical Data Update on Friday, December 14, 2018
EXTON, Pa., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined
Wednesday, December 12, 2018
AGTC Announces Topline Interim Six-Month Data from Phase 1/2 X-Linked Retinoschisis Clinical Study; Termination of Biogen Collaboration
- Results from XLRS study support general safety and tolerability of AGTC’s gene delivery platform but did not demonstrate signs of clinical activity at interim six-month time point -- AGTC to regain rights to five clinical and preclinical development programs; Biogen terminates collaboration
Wednesday, December 12, 2018
VBI Vaccines Announces Proposed Public Offering of Common Shares
CAMBRIDGE, Mass., Dec. 12, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that it has commenced an underwritten public offering of its common
Wednesday, December 12, 2018
Veterinarians are in control: Medical insurance for pets can avoid pitfalls of human health insurance
SEATTLE, Dec. 12, 2018 (GLOBE NEWSWIRE) -- While human health insurance models – each with its own set of problems – are debated all over the world, medical insurance for pets is currently avoiding such criticism and can continue to do so with input from veterinarians. Human medical
Wednesday, December 12, 2018
Advanzeon Solutions, Inc.’s Wholly-Owned Subsidiary Pharmacy Value Management Solutions, Inc. Announces Medical Director and Members of Its Medical
TAMPA, Fla., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Advanzeon Solutions, Inc.’s (OTCBB:CHCR) ("Advanzeon") wholly-owned subsidiary, Pharmacy Value Management Solutions, Inc. ("PVMS") (collectively, the "Company"), announced today that its Medical Director and many members of its Medical Advisory
Wednesday, December 12, 2018
Easton Pharmaceuticals Provides Company Update Including Hotel Acquisition in Toronto, BAYER Agreement and Casino Resort in Greece
TORONTO, ON, Dec. 12, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Easton Pharmaceuticals Inc. (OTC: EAPH) Provides Company update including Hotel Acquisition in Toronto, BAYER Distribution Agreement for Mexico, as well as the Casino and Hotel Resort acquisition in Greece. As previously
Wednesday, December 12, 2018
Aptose Presents Highlights From CG-806 KOL Event
Dr. Brian Druker Reviews AML and B-cell Cancer Treatment Landscape and Provides Update on Novel Multi-Cluster Kinase Inhibitor CG-806SAN DIEGO and TORONTO, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) released highlights from a Key Opinion Leader (KOL)
Wednesday, December 12, 2018
Ceapro Inc. Presents PGX Technology at the Society of Cosmetic Chemists’ 72nd Annual Scientific Meeting and Technology Showcase
EDMONTON, Alberta, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Paul Moquin,
Wednesday, December 12, 2018
Phoenix Life Sciences International Is Now Accepting Bids for Hemp CBD Producers and Manufacturers
DENVER, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Phoenix Life Sciences International Limited (OTC: PLSI) (“Phoenix Life”), an international adaptive healthcare solutions company, today announced that it is now accepting bids from U.S. licensed producers of industrial hemp to supply various products
Wednesday, December 12, 2018
iAnthus and MPX Announce Receipt of Interim Court Order
NEW YORK and TORONTO, Dec. 12, 2018 (GLOBE NEWSWIRE) -- iAnthus Capital Holdings, Inc. (“iAnthus” or “the Company”), (CSE: IAN, OTCQB: ITHUF) and MPX Bioceutical Corporation (“MPX”) (CSE: MPX; OTC:MPXEF) announced today that on December 10, 2018, MPX was granted an interim order from
Wednesday, December 12, 2018
CV Sciences, Inc. Receives Nutritional Outlook’s 2018 Best of the Industry Award
Company’s industry-dominating hemp extract brand, PlusCBD Oil™ wins Best Retail/Brand Product category LAS VEGAS, Dec. 12, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB: CVSI) (the “Company”, “CV Sciences”, “our” or “we”), preeminent supplier and manufacturer of
Wednesday, December 12, 2018
Terra Tech Subsidiary Edible Garden to Participate in The New York Produce Show and Conference December 12th
IRVINE, Calif., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Terra Tech Corp. (TRTC) ("Terra Tech") or (the "Company"), a vertically integrated cannabis-focused agriculture company, today announced that its wholly-owned subsidiary, Edible Garden, will participate in the New York Produce Show and Conference,
Wednesday, December 12, 2018
Preclinical Data on Vaccinex, Inc. Anti-SEMA4D Monoclonal Antibody in Combination with Checkpoint Inhibitors Published in Cancer Immunology Research
ROCHESTER, N.Y., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative
Wednesday, December 12, 2018
Zosano Receives Conditional FDA Acceptance of Proposed Brand Name Qtrypta™ for M207
FREMONT, Calif., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proposed brand name
Wednesday, December 12, 2018
Kane Biotech Launches Four New bluestem™ Products
WINNIPEG, Manitoba, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”), today announced it will be launching 4 new products under its bluestem™ brand in Canada and the United States in the first quarter of 2019. The four
Wednesday, December 12, 2018
XBiotech’s Results from Phase 2 Atopic Dermatitis Study Suggest New Drug to Treat Skin Disease
Bermekimab Therapy Rapidly and Significantly Reduces DiseaseAUSTIN, Texas, Dec. 12, 2018 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that its open label, proof of concept, multicenter study using bermekimab to treat patients with moderate to severe atopic dermatitis (AD) has
Wednesday, December 12, 2018
